Axon Therapies

Executive Summary

Axon Therapies is a private, clinical-stage medical device company addressing the significant unmet need in heart failure with preserved ejection fraction (HFpEF), a condition affecting millions worldwide with limited treatment options. The company's proprietary Splanchnic Ablation for Volume Management (SAVM) technology offers a minimally invasive, catheter-based procedure to ablate the greater splanchnic nerve, reducing sympathetic overdrive and improving fluid volume management. This implant-free, outpatient approach aims to rebalance cardiac function and enhance quality of life. With a strong scientific rationale and a seasoned management team, Axon is positioned to disrupt the HFpEF treatment landscape. The company is currently advancing through preclinical and early clinical stages, and its success hinges on demonstrating safety and efficacy in upcoming trials.

Upcoming Catalysts (preview)

• Q2 2026FDA IDE approval for pivotal trial75% success
• Q3 2026First patient enrolled in pivotal trial70% success
• Q4 2026Presentation of interim data from feasibility study65% success